Phunziro Latsopano la Chithandizo cha Acute Myeloid Leukemia

Moleculin Biotech, Inc. lero yalengeza kuti yalandira chilolezo kuchokera ku dipatimenti yolembetsa yamankhwala yaku Poland (URPL), komanso chivomerezo chofunikira cha Komiti ya Ethics, kuti ipitilize mayeso ake a Phase 1/2 ku Poland a Annamycin (L -ANN) pamodzi ndi Cytarabine (Ara-C) pochiza anthu omwe ali ndi matenda oopsa a myeloid leukemia (AML) omwe amatsutsa kapena kubwereranso pambuyo pa chithandizo chamankhwala.

Mayesero a Phase 1/2 L-ANN/ARA-C (AnnAraC) (MB-106), kuyesa kwa zilembo zotseguka, kumawonjezera chitetezo ndi kuchuluka kwa mlingo kuchokera ku mayesero awiri omwe adatsirizidwa bwino ndi wothandizira mmodzi Annamycin AML Phase 1 (MB- 104 ndi MB-105) ku US ndi Europe ndi zomwe zafotokozedwa pansipa. Kafukufukuyu akuyembekezeka kuyamba kulembetsa odwala mu theka loyamba la 2022.

Walter Klemp, Wapampando ndi Chief Executive Officer wa Moleculin adati, "Ndife okondwa ndi ndemanga zabwino zochokera ku URPL ndipo tili okondwa kutengapo gawo lina poyambitsa kuyesa kofunikiraku. Polimbikitsidwa ndi zomwe zapezeka pano, tikukhulupirira kuti kuphatikiza kwa Annamycin ndi Cytarabine kumatha kupititsa patsogolo ntchito motsutsana ndi AML. Ndi chilolezo choti chipitirire tsopano, gulu lathu likuyesetsa kuti kuyesaku kuchitike mwachangu komanso moyenera momwe tingathere. Malingana ndi chithandizo chopitilira chomwe chinaperekedwa kuchokera kwa madokotala a ku Poland pa mayesero awa a AnnAraC, tikukhulupirira kuti tidzatha kukhalabe panjira kuti mlanduwu uchitike kotala lino ndikulimbikitsanso ntchito yolembera odwala. Tikuyesetsanso kukulitsa mayesowa kumayiko ena ku Europe kuti tithandizire kupititsa patsogolo kuchuluka kwa anthu olemba anzawo ntchito. ”

Chofunika kwambiri, Annamycin wawonetsanso kusowa kwa cardiotoxicity m'mayesero angapo azachipatala a anthu, kuphatikiza kuyesa kosalekeza kochizira matenda obwerera m'mbuyo kapena osasinthika a AML ndi ma metastases am'mapapo a minofu yofewa (STS). Annamycin ndi m'badwo wotsatira wa anthracycline wa Company womwe wawonetsedwa m'zinyama kuti ziunjike m'mapapo mpaka kuwirikiza katatu mulingo wa doxorubicin, komanso kuwonetsa kuthekera kopewa kukana kugwiritsa ntchito mankhwala ambiri komwe kumachepetsa mphamvu ya doxorubicin. ndi mankhwala ena otchedwa anthracycline. Kuphatikiza apo, kutengera chidziwitso chowonjezera chazinyama chochokera ku kafukufuku wothandizidwa, Annamycin kuphatikiza ndi Cytarabine adawonetsa kusintha kwa 30% pakupulumuka kwapakatikati (OS) poyerekeza ndi Annamycin ngati wothandizira m'modzi komanso kuwonjezeka kwa 68% kwa OS poyerekeza ndi Cytarabine yokha. Deta iyi idaperekedwa posachedwapa pa Msonkhano Wapachaka wa 241nd & Exposition of the American Society for Hematology ("ASH") pansi pa mutu wakuti: "High Efficacy of Liposomal Annamycin (L-ANN or Annamycin) in Combination with Cytarabine in Syngeneic p62-null AML Mouse Model."

Mu Januware 2022, kampaniyo idanenanso kuti idalandira kuwunika kodziyimira pawokha kwachitetezo cha odwala 30 oyamba m'mayesero ake atatu a Gawo 1 azachipatala ndi Annamycin yolunjika ku AML (MB-104 ndi MB-105) komanso ma metastases of soft minofu sarcoma m'mapapo (STS Lung) kapena MB-107, zomwe zinatsimikizira kuti panalibe umboni wa cardiotoxicity. Kutengera ndi zomwe zidawonedwa mgulu lachisanu komanso lomaliza la kuchuluka kwa mayeso a MB-105, Kampani inanena kuti Annamycin adawonetsa kuyankha konse (ORR) kwa 60%. Izi zinaphatikizapo mayankho awiri (PRs) ndi yankho limodzi lathunthu ndi kuchira kosakwanira kwa neutrophils ndi / kapena mapulateleti (CRi). Itafika bwinobwino pa RP2D ya 240 mg/m2 mu kuyesa kwa MB-105, Kampani inamaliza kulemba anthu kuti ayesetse.